Seth Lederman - Feb 15, 2022 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role: Chief Executive Officer, Director
Signature: /s/ Seth Lederman
Stock symbol: TNXP
Transactions as of: Feb 15, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/17/2022, 04:17 PM
Previous filing: Sep 28, 2021
Next filing: Mar 28, 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TNXP	Stock Option	Award	$0	+5M		$0.00	5M	Feb 15, 2022	Common Stock	5M	$0.21	Direct	F1, F3
transaction	TNXP	Stock Option	Award	$0	+5M		$0.00	5M	Feb 15, 2022	Common Stock	5M	$0.41	Direct	F2, F3
transaction	TNXP	Stock Option	Award	$0	+5M		$0.00	5M	Feb 15, 2022	Common Stock	5M	$0.62	Direct	F2, F3
transaction	TNXP	Stock Option	Award	$0	+5M		$0.00	5M	Feb 15, 2022	Common Stock	5M	$0.83	Direct	F2, F3

Showing 1 to 4 of 4 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F2	10% of the option vests on the first anniversary of issuance, 10% on the second anniversary of issuance, 40% on the third anniversary of issuance, and 40% on the fourth anniversary of issuance.
F3	The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.